Pfizer Inc. (NYSE:PFE) Stake Boosted by Coerente Capital Management

Coerente Capital Management raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.8% in the 4th quarter, Holdings Channel reports. The firm owned 593,678 shares of the biopharmaceutical company’s stock after purchasing an additional 4,626 shares during the quarter. Pfizer comprises about 2.9% of Coerente Capital Management’s investment portfolio, making the stock its 18th biggest holding. Coerente Capital Management’s holdings in Pfizer were worth $15,750,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Symphony Financial Ltd. Co. grew its position in shares of Pfizer by 15.5% during the 4th quarter. Symphony Financial Ltd. Co. now owns 47,477 shares of the biopharmaceutical company’s stock valued at $1,252,000 after buying an additional 6,371 shares during the last quarter. Costello Asset Management INC boosted its stake in Pfizer by 35.1% in the fourth quarter. Costello Asset Management INC now owns 76,900 shares of the biopharmaceutical company’s stock valued at $2,040,000 after acquiring an additional 19,975 shares during the period. Abundance Wealth Counselors bought a new stake in shares of Pfizer in the 4th quarter worth approximately $702,000. Independence Bank of Kentucky boosted its position in Pfizer by 4.9% during the 4th quarter. Independence Bank of Kentucky now owns 73,913 shares of the biopharmaceutical company’s stock valued at $1,961,000 after purchasing an additional 3,457 shares during the period. Finally, Blossom Wealth Management grew its stake in Pfizer by 5.5% during the 4th quarter. Blossom Wealth Management now owns 13,022 shares of the biopharmaceutical company’s stock worth $345,000 after buying an additional 684 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

PFE opened at $26.51 on Friday. The business has a fifty day simple moving average of $26.27 and a 200-day simple moving average of $27.87. The firm has a market cap of $150.20 billion, a PE ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the company earned ($0.17) EPS. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Analysts Set New Price Targets

PFE has been the subject of several analyst reports. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.